why is compounded tirzepatide still being sold FDA ban on tirzepatide: Switch to name brand medications COMPOUNDED TIRZEPATIDE
Description
Alrouji et al
April 11 Product: AstraZenecas Fasnera Indication: Asthma AstraZeneca won a label expansion Thursday for Fasnera, a subcutaneous IL-5 receptor blocker, for the add-on maintenance treatment of severe eosinophilic asthma in kids 6 to 11 years of age
This can be attributed to the medications multifaceted mechanism of action, which not only helps regulate blood sugar but also promotes satiety and facilitates weight loss
10.3390/jpm12030454 55 RosenthalR
If you decide to discontinue Tirzepatide, its important to do so under the guidance of a healthcare professional
